About this Research Topic
RNA viruses continue to emerge or re-emerge with devastating economic and health impacts on humans and animals and pose a significant threat as evidenced in recent decades. There are several RNA viruses causing respiratory disease. Vaccination remains the most reliable strategy for mitigating the emergence and spread of these pathogens. The level of success associated with mRNA-based vaccine against SARS-CoV-2 has widely encouraged the current acceleration towards mRNA vaccine development. mRNA vaccines have been/are being evaluated against influenza virus, human immunodeficiency virus, etc. The mRNA vaccine technology enables the rapid modification of immunogen to respond to the emergence of new variants and have effectively demonstrated their adaptability and potential for eliciting a superior immune response in comparison to other approaches. Despite several advantages, numerous areas exist for further optimization and establishing mRNA vaccines as a leading strategy.
In this Research Topic, we discuss the recent advancement in the development of candidate mRNA vaccines against emerging RNA viruses causing respiratory disease, leading to important human public health problems.
The mRNA vaccine technology allows the rational design of candidate vaccines to have the defined molecular basis of immunogenicity and protective immunity. Multiple factors are crucial for the development of effective mRNA vaccines, including the choice of immunogens and the delivery systems to elicit host immune responses. In this issue authors will be encouraged to discuss the development of candidate mRNA vaccines against various RNA viruses in context of extended stability, long-term immunity, potential of eliciting mucosal immunity and/or how candidate mRNA vaccines can be aligned with the World Health Organization target product profiles used to guide human vaccine development.
This Research topic aims to address and highlight critical research needed to allow the development and advancement of candidate mRNA vaccines against emerging respiratory RNA viruses. We welcome the submissions of Original Research, Review/Mini-review, Methods, Opinion, and General Commentary articles that cover, but are not limited to, the following sub-topics:
• Efficacy or effectiveness of candidate mRNA vaccines with the licensed vaccines targeting the same pathogens
• Novel mRNA-based vaccine platforms and/or delivery vectors
• Development of broadly protective or universal vaccines
• Developing vaccines with increased long-term mucosal immunity
• Novel strategies for increasing mRNA vaccine stability
• mRNA vaccines capable of inducing specific adaptive immune response
• Novel delivery vehicles for formulating mRNA vaccines
Dr. Swagata Kar is an employee of BIOQUAL Inc., which is involved in pre-clinical testing of various vaccines, small molecules therapeutics, etc., but not involved in manufacturing. The other Topic Editors declare no competing interests with regard to the topic theme.
In this Research Topic, we discuss the recent advancement in the development of candidate mRNA vaccines against emerging RNA viruses causing respiratory disease, leading to important human public health problems.
The mRNA vaccine technology allows the rational design of candidate vaccines to have the defined molecular basis of immunogenicity and protective immunity. Multiple factors are crucial for the development of effective mRNA vaccines, including the choice of immunogens and the delivery systems to elicit host immune responses. In this issue authors will be encouraged to discuss the development of candidate mRNA vaccines against various RNA viruses in context of extended stability, long-term immunity, potential of eliciting mucosal immunity and/or how candidate mRNA vaccines can be aligned with the World Health Organization target product profiles used to guide human vaccine development.
This Research topic aims to address and highlight critical research needed to allow the development and advancement of candidate mRNA vaccines against emerging respiratory RNA viruses. We welcome the submissions of Original Research, Review/Mini-review, Methods, Opinion, and General Commentary articles that cover, but are not limited to, the following sub-topics:
• Efficacy or effectiveness of candidate mRNA vaccines with the licensed vaccines targeting the same pathogens
• Novel mRNA-based vaccine platforms and/or delivery vectors
• Development of broadly protective or universal vaccines
• Developing vaccines with increased long-term mucosal immunity
• Novel strategies for increasing mRNA vaccine stability
• mRNA vaccines capable of inducing specific adaptive immune response
• Novel delivery vehicles for formulating mRNA vaccines
Dr. Swagata Kar is an employee of BIOQUAL Inc., which is involved in pre-clinical testing of various vaccines, small molecules therapeutics, etc., but not involved in manufacturing. The other Topic Editors declare no competing interests with regard to the topic theme.
Keywords: mRNA vaccine, RNA viruses, immunogenicity, mucosal immunity, influenza, SARS-CoV-2, respiratory disease
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
